Arcellx Company Insiders
| ACLX Stock | USD 114.47 0.14 0.12% |
Arcellx's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Arcellx suggests that virtually all insiders are panicking. Arcellx employs about 209 people. The company is managed by 13 executives with a total tenure of roughly 488 years, averaging almost 37.0 years of service per executive, having 16.08 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2026-02-27 | Rami Elghandour | Disposed 89916 @ 113.92 | View | ||
| 2026-01-14 | Christopher Heery | Disposed 5882 @ 68.51 | View | ||
| 2026-01-13 | Christopher Heery | Disposed 7437 @ 65.51 | View | ||
| 2026-01-12 | Christopher Heery | Disposed 6131 @ 64.15 | View | ||
| 2025-11-17 | Christopher Heery | Disposed 340 @ 90 | View | ||
| 2025-09-30 | Christopher Heery | Disposed 21034 @ 81.28 | View | ||
| 2025-09-29 | Christopher Heery | Disposed 73 @ 80.16 | View | ||
| 2025-09-26 | Christopher Heery | Disposed 12396 @ 80.12 | View | ||
| 2025-09-19 | Christopher Heery | Disposed 300 @ 80 | View | ||
| 2025-09-18 | Christopher Heery | Disposed 3343 @ 80.01 | View | ||
| 2025-06-10 | Kavita Patel | Disposed 1500 @ 67.36 | View | ||
| 2025-05-20 | Kavita Patel | Disposed 1500 @ 58.43 | View | ||
| 2025-04-29 | Kavita Patel | Disposed 1500 @ 64.2 | View | ||
| 2025-04-08 | Kavita Patel | Disposed 1500 @ 57.5 | View | ||
| 2025-03-18 | Kavita Patel | Disposed 1500 @ 71.64 | View |
Following insider trading sentiment in Arcellx can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Trending Equities provides context for diversified portfolio construction. Clearer exposure analysis supports long-term portfolio balance. This reflects a position in Arcellx in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.Arcellx's Workforce Through the Years
A workforce review of Arcellx matters because hiring and staffing trends often say something about growth plans, cost discipline, and management expectations. Current projections suggest a workforce around about 210 employees by April 2026, which should be reviewed alongside revenue and margin trends.Arcellx Management Team Effectiveness
The company has return on total asset (ROA) of -24.05 % which means that it has lost $24.05 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of -53.42 %, meaning that it created substantial loss on money invested by shareholders.As of earlier this week, Common Stock Shares Outstanding is anticipated to decline to approximately 40.2 M. In addition to that, Net Loss is projected to grow to approximately -161.3 M
Arcellx Stock Ownership Analysis
About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.07. Arcellx had not issued any dividends in recent years.Reviewing share-based compensation in Arcellx helps investors understand how management balances employee incentives against dilution risk. Shares outstanding are near 58.5 M. That is why investors should compare compensation intensity with revenue growth, margin progress, and free-cash-flow generation.
Arcellx Quarterly Liabilities And Stockholders Equity | 603.99 Million |
Arcellx Insider Trades History
Reviewing insider ownership in Arcellx helps investors understand how much of the equity base is controlled by people involved in running the business. Insiders currently hold about 12.89% of outstanding shares. Investors usually want to know whether that level supports alignment without creating excessive control risk. View all of Arcellx's insider trades
Arcellx Stock Institutional Investors
Institutional ownership matters in Arcellx because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Ra Capital Management, Llc | 2025-12-31 | 1.3 M | T. Rowe Price Associates, Inc. | 2025-09-30 | 1.3 M | Citadel Advisors Llc | 2025-09-30 | 1 M | Hhg Plc | 2025-09-30 | 1 M | Geode Capital Management, Llc | 2025-09-30 | 926.3 K | Capital World Investors | 2025-09-30 | 783 K | Cormorant Asset Management, Llc | 2025-09-30 | 775 K | Woodline Partners Lp | 2025-12-31 | 737.8 K | Bamco Inc | 2025-12-31 | 609.7 K | T. Rowe Price Investment Management,inc. | 2025-09-30 | 6.4 M | Paradigm Biocapital Advisors Lp | 2025-12-31 | 5.7 M |
Arcellx Insider Trading Activities
Insider trading disclosures for Arcellx offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 6.69 Billion. Used properly, these records are better for context than for blind buy-or-sell signals.
Arcellx Outstanding Bonds
Reviewing Arcellx bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| ARCHER DANIELS MIDLAND 75 Corp BondUS039483AM40 | View | |
| US039483AN23 Corp BondUS039483AN23 | View | |
| ARCHER DANIELS MIDLAND 25 Corp BondUS039483BL57 | View | |
| ARCHER DANIELS MIDLAND 45 Corp BondUS039483BQ45 | View | |
| ARCHER DANIELS MIDLAND 4535 Corp BondUS039483BE15 | View | |
| US039483AT92 Corp BondUS039483AT92 | View | |
| US039483AS10 Corp BondUS039483AS10 | View | |
| ADM 29 01 MAR 32 Corp BondUS039482AD67 | View |
Arcellx Corporate Filings
13A | 6th of March 2026 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 4th of March 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 27th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 26th of February 2026 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 25th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 24th of February 2026 An amendment to the original Schedule 13D filing | ViewVerify |
| 23rd of February 2026 Other Reports | ViewVerify | |
F4 | 19th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Shares in Circulation | First Issued 2020-12-31 | Previous Quarter 56.6 M | Current Value 56.3 M | Average Shares Outstanding 42.8 M | Quarterly Volatility 13.6 M |
Arcellx Stock Holders Distribution
Institutional ownership analysis for Arcellx matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Arcellx Market Cap and Value
Arcellx Workforce Comparison
Arcellx is rated below average. in number of employees category among its top compatitors. The total workforce of Health Care industry is presently estimated at about 4,829. Arcellx holds roughly 209 in number of employees claiming about 4% of equities under Health Care sector.
Arcellx Insider Trading History
Insider trading disclosures for Arcellx offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 6.69 Billion. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 0.5417 | 13 | 24 | 634,102 | 933,443 |
| 2025-09-01 | 0.25 | 2 | 8 | 4,207 | 584,084 |
| 2025-06-01 | 1.0909 | 12 | 11 | 77,867 | 46,664 |
| 2025-03-01 | 0.4043 | 19 | 47 | 1,680,368 | 496,765 |
| 2024-12-01 | 0.3235 | 11 | 34 | 75,179 | 154,273 |
| 2024-09-01 | 0.4146 | 17 | 41 | 135,358 | 270,716 |
| 2024-06-01 | 0.5217 | 12 | 23 | 128,064 | 185,652 |
| 2024-03-01 | 0.4194 | 13 | 31 | 874,416 | 872,435 |
| 2023-12-01 | 0.1667 | 1 | 6 | 120,000 | 744,263 |
| 2023-09-01 | 0.5 | 2 | 4 | 6,000 | 12,000 |
| 2023-06-01 | 0.5484 | 17 | 31 | 135,068 | 2,126,986 |
| 2023-03-01 | 1.3333 | 12 | 9 | 758,831 | 138,684 |
| 2022-12-01 | 1.0 | 20 | 20 | 197,634 | 14,207,181 |
| 2022-03-01 | 0.6765 | 23 | 34 | 25,038,109 | 25,627,997 |
Arcellx Notable Stakeholders
Stakeholders matter for Arcellx because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Helen Kim | VP Affairs | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Kate Aiken | Chief Officer | Profile | |
| Michelle Gilson | Chief Officer | Profile | |
| Myesha Lacy | Chief Officer | Profile | |
| Christopher MD | Chief Officer | Profile | |
| Narinderjeet MS | Chief Officer | Profile | |
| Rami Elghandour | CEO Chairman | Profile | |
| Aileen Fernandes | Chief Officer | Profile | |
| MS JD | General Counsel | Profile | |
| Heba Nowyhed | Chief Officer | Profile | |
| David Tice | Chief Officer | Profile | |
| Neeraj Teotia | Chief Officer | Profile |
Arcellx Management and Insider Overview
Arcellx is a large-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Executive background, tenure, and turnover can influence how investors interpret strategic shifts. We evaluate Arcellx through the lens of long-term portfolio construction and diversification efficiency.
Methodology
Unless otherwise specified, financial data for Arcellx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Arcellx (USA Stocks:ACLX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Insider activity and ownership figures are derived from regulatory filings, including SEC Form 4 submissions where applicable.
Assumptions
We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Arcellx is covered by 18 analysts. 9 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, Guggenheim Securities, Deutsche Bank, Raymond James, Citigroup, HSBC Global Research, among others. Updates may occur throughout the day.
Arcellx Workforce Analysis
Investors reviewing Arcellx can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Arcellx Manpower Efficiency
Return on Arcellx Manpower
| Revenue Per Employee | 106.6K | |
| Revenue Per Executive | 1.7M | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 17.6M | |
| Working Capital Per Employee | 1.7M | |
| Working Capital Per Executive | 27.5M |
Popular Tools for Arcellx Stock analysis
| Stocks Directory Find actively traded stocks across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |